✦ LIBER ✦

Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma

✍ Scribed by M. LAPECORELLA; M. NAPOLITANO; M. TUDINI; G. BRUERA; A. LUCCHESI; A. V. GIORDANO; G. MARIANI; E. RICEVUTO

Book ID: 108775357
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 82 KB
Volume: 16
Category: Article
ISSN: 1351-8216
DOI: 10.1111/j.1365-2516.2009.02114.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Targeting chemokines as a therapeutic op

Targeting chemokines as a therapeutic option for hepatocellular carcinoma: A reality or just a fantasy?

✍ Jun Yu 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB

GLUT1 as a therapeutic target in hepatoc

GLUT1 as a therapeutic target in hepatocellular carcinoma

✍ Amann, Thomas; Hellerbrand, Claus 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 766 KB

Laparoscopic liver resections for hepato

Laparoscopic liver resections for hepatocellular carcinoma. Is it a feasible option for patients with liver cirrhosis?

✍ R. Santambrogio; L. Aldrighetti; M. Barabino; C. Pulitanò; M. Costa; M. Montorsi 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 276 KB

Myositis due to Sorafenib intake in a pa

Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma

✍ Antonio Diaz-Sanchez; Nuria Rodriguez-Salas; Teresa Aramendi; Eva Balbin 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 276 KB

Probable sorafenib-induced reversible en

Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma

✍ Erkan Dogan; Sercan Aksoy; Cagatay Arslan; Didem S. Dede; Kadri Altundag 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 107 KB

Sorafenib therapy in patients with hepat

Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation

✍ Ian A. Rowe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB 👁 1 views

The team of Liu et al. generated endoderm-derived human induced pluripotent stem (iPS) cells from primary hepatocytes. 1 However, they generated human iPS cells by using viral transgenes. 1 Clinical applications of human iPS cells require avoiding viral transgenes. On the other hand, the reprogrammi